Lol mero thinks he's taught us something. He still cannot explain why the FDA would not understand astx technology. To clear the record, I understood that the street would not like the revision. Mero had no clue, if he did, he wouldn't be whinning everyday as the shareprice went up.
Until this company has a second drug, we are at the mercy of dacogen growing revenues. I had 7500 shares in my IRA that I can trade. So I made a smart call here. No taxes and I can buy back near 500 additional shares. I believe long term that this company has a terrific shots at a second and third drug appovals. Then it becomes a target for a buyout.
Good questions max. Very well thought out. I believe the impairment charge, maybe related to mp-470 writedown and climb? I think at7519 is partnered now. See if I'm right. I plan on looking at ASH site in the next few days. Usually you can start reading what they will present.
Good work. I had fired of fa e-mail to tim. I wasn't too nice about the claims of shareholder appreciation this year. Way to many broken promises.
I stated for years now, once they have a misstep with sgi-110, I'm gone.
1. Eisai reported sales of $110M for Dacogen in the latest quarter.
2. Eisai in one of its charts showed that Dacogen has been submitted for approval in Mexico. Would call this a good thing. Maybe they don't see the generic threat? I checked the transcript from the last Celgene CC and they made no reference of a generic threat.
I can't either which is why I bought more shares at $2.35 today. My original purchase was at $3.25. I'm hoping we get back of $3 in the near term. I don't think the #'s were that bad at all plus the company looks be reporting a positive # next quarter. The market and the biotech sector is down big as a whole today.